The writing is on the wall for Realm Therapeutics which has decided to discontinue all of its drug development programs and put up the 'for sale' sign following the high-profile failure this summer of its mid-stage atopic dermatitis candidate.
Realm, which is listed on London's AIM exchange but is based in Malvern, PA, has been struggling since August when...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
